RGC Stock Analysis: Buy, Sell, or Hold?
RGC - Regencell Bioscience Holdings Limited Ordinary Shares
$8.79
-2.29 (-20.67%)
▼
5d:
-47.46%
30d:
-65.93%
90d:
-64.01%
WAIT
LOW Confidence
Analysis Updated: Jun 24, 2026 12:00 AM ET
Earnings: Jun 02, 2026
0d
Get Alerted When RGC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: RGC is down 47.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: RGC is down 47.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: RGC is currently trading at $8.79, which is considered oversold relative to its 30-day fair value range of $15.22 to $26.01.
Technical Outlook: Technically, RGC is in a downtrend. The price is currently testing key support at $8.90. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 20.7% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, RGC is in a downtrend. The price is currently testing key support at $8.90. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 20.7% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$15.22 -
$26.01
Company Quality Score
46/100
(HOLD)
Options IV Signal
44th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
73.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 44th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-20.7%)
- WARNING: Recommendation downgraded due to -47.5% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$15.22 -
$26.01
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$1.89
(21.5%)
Support & Resistance Levels
Support Level
$8.90
Resistance Level
$21.00
Current Trend
Downtrend
Technical data as of
Jun 24, 2026
Fundamental Context
Share & Embed Analysis
Last updated: June 24, 2026 3:46 PM ET
Data refreshes hourly during market hours. Next update: 4:46 PM
Data refreshes hourly during market hours. Next update: 4:46 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RGC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$194 | 59 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$105 | 60 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$125 | 57 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$665 | 60 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 59 HOLD |
